1. Which of the following correctly identifies the rate-limiting enzymatic step in catecholamine biosynthesis and the substrate on which it acts?

• A) Dopamine beta-hydroxylase acts on dopamine to produce norepinephrine -- this is the rate-limiting step in catecholamine biosynthesis and the primary target of drugs designed to reduce sympathetic neurotransmitter production; inhibition of dopamine beta-hydroxylase by disulfiram accounts for its cardiovascular side effects in patients being treated for alcohol dependence.
• B) Tyrosine hydroxylase acts on L-tyrosine to produce L-DOPA -- this is the rate-limiting enzymatic step in catecholamine biosynthesis; tyrosine hydroxylase requires tetrahydrobiopterin as a cofactor and is subject to end-product inhibition by catecholamines, providing an autoregulatory mechanism that limits NE synthesis when cytoplasmic catecholamine concentrations are high; metyrosine (alpha-methyl-p-tyrosine) inhibits tyrosine hydroxylase and is used to reduce catecholamine synthesis in pheochromocytoma management.
• C) DOPA decarboxylase (aromatic L-amino acid decarboxylase) acts on L-tyrosine to produce dopamine -- this is the rate-limiting step in catecholamine biosynthesis; carbidopa inhibits DOPA decarboxylase and is co-administered with levodopa in Parkinson's disease treatment to prevent peripheral conversion of levodopa to dopamine before it crosses the blood-brain barrier.
• D) Phenylethanolamine N-methyltransferase (PNMT) acts on norepinephrine to produce epinephrine -- this is the rate-limiting step in catecholamine biosynthesis and occurs exclusively in adrenal chromaffin cells; PNMT requires cortisol from the adrenal cortex for induction, explaining why the adrenal medulla is anatomically positioned within the adrenal gland rather than as a separate structure.
• E) Monoamine oxidase (MAO) acts on tyramine to produce dopamine -- this is the rate-limiting step in catecholamine biosynthesis in sympathetic nerve terminals; inhibition of MAO by phenelzine and tranylcypromine reduces catecholamine biosynthesis, explaining their antihypertensive effects in addition to their antidepressant properties.

2. The vesicular monoamine transporter (VMAT2) performs which essential function in sympathetic neurotransmission, and which pharmacological agent exploits this transporter to deplete norepinephrine stores?

• A) VMAT2 transports norepinephrine from the cytoplasm of sympathetic nerve terminals back into synaptic vesicles for storage, using the proton gradient maintained by vacuolar H+-ATPase as its energy source; reserpine irreversibly inhibits VMAT2, preventing vesicular NE uptake, causing cytoplasmic NE to be degraded by MAO and producing profound and prolonged sympathetic denervation; reserpine was used as an antihypertensive but abandoned due to its CNS effects (depression, sedation) from depletion of central monoamine stores.
• B) VMAT2 transports norepinephrine from synaptic vesicles into the cytoplasm for release by exocytosis-independent diffusion, providing a reserve mechanism for NE release when vesicular exocytosis is insufficient during intense sympathetic stimulation; reserpine activates VMAT2 to enhance this non-exocytotic NE release, producing its antihypertensive effect through paradoxical initial sympathomimesis followed by depletion.
• C) VMAT2 transports dopamine from the cytoplasm into synaptic vesicles where dopamine beta-hydroxylase converts it to norepinephrine inside the vesicle lumen; guanethidine inhibits VMAT2 by competing with dopamine at the transporter, preventing NE synthesis within the vesicle and producing sympatholysis by a biosynthetic rather than storage-depletion mechanism.
• D) VMAT2 is expressed exclusively in adrenal chromaffin cells and is responsible for concentrating epinephrine into chromaffin granules before calcium-triggered exocytosis; in sympathetic nerve terminals, NE storage in vesicles is accomplished by a different transporter (VMAT1); tetrabenazine selectively inhibits adrenal VMAT2 to reduce epinephrine secretion in pheochromocytoma without affecting peripheral sympathetic NE stores.
• E) VMAT2 transports norepinephrine from the cytoplasm into storage vesicles, protecting it from cytoplasmic MAO degradation; reserpine irreversibly inhibits VMAT2, trapping NE in the cytoplasm where it is degraded by MAO, depleting vesicular stores; this depletion is prolonged because reserpine's inhibition persists until new VMAT2 protein is synthesized, requiring days to weeks for full recovery of sympathetic neurotransmission.

3. Which of the following correctly identifies the two distinct membrane transporters responsible for terminating norepinephrine action at the sympathetic neuroeffector junction, and differentiates their pharmacological significance?

• A) The norepinephrine transporter (NET, Uptake 1) is expressed on sympathetic postganglionic nerve terminals and is the primary mechanism for terminating NE action at the neuroeffector junction -- it transports NE back into the presynaptic terminal with high affinity and low capacity; the extraneuronal monoamine transporter (EMT/OCT3, Uptake 2) is expressed on postsynaptic effector cells and surrounding non-neuronal tissues with lower affinity but higher capacity; NET is the primary target of tricyclic antidepressants, cocaine, and atomoxetine (which block reuptake); OCT3 becomes pharmacologically important when NET is blocked or absent.
• B) The norepinephrine transporter (NET) is expressed on adrenal chromaffin cells and is responsible for the reuptake of circulating epinephrine into the adrenal medulla for repackaging and re-secretion; the extraneuronal monoamine transporter (EMT) is expressed on sympathetic nerve terminals and is responsible for the primary clearance of synaptically released NE; beta-blockers inhibit both transporters simultaneously, explaining their ability to both reduce heart rate and prolong the duration of action of exogenously administered catecholamines.
• C) NET (Uptake 1) and OCT3/EMT (Uptake 2) both transport NE into presynaptic sympathetic terminals, but via different ion-coupling mechanisms -- NET is sodium-coupled while OCT3 is proton-coupled; the clinical distinction is that NET operates at rest while OCT3 is activated only during high-frequency sympathetic stimulation when synaptic NE concentrations exceed NET's Km; drugs that block NET (cocaine, tricyclics) are therefore only effective during intense sympathetic activation.
• D) NET is responsible for approximately 70-90% of NE clearance at most sympathetic neuroeffector junctions through high-affinity sodium-dependent reuptake into the presynaptic terminal, where NE is either repackaged into vesicles via VMAT2 or degraded by MAO-A; OCT3/EMT provides lower-affinity higher-capacity NE clearance in extraneuronal tissues (cardiac myocytes, smooth muscle, liver, kidney) and becomes quantitatively important for clearance of circulating catecholamines; NET blockade by cocaine produces sympathomimesis by accumulating NE at postsynaptic receptors, while NET blockade by atomoxetine produces therapeutic noradrenergic enhancement in ADHD.
• E) NET and EMT are both located exclusively on the postsynaptic effector cell membrane -- they function as NE degradation enzymes rather than transporters, with NET cleaving the catechol ring and EMT deaminating the ethylamine side chain; together these two enzymes account for complete NE inactivation at the neuroeffector junction; drugs that inhibit NET (tricyclic antidepressants) therefore prevent NE degradation at the postsynaptic membrane, prolonging receptor activation.

4. Monoamine oxidase (MAO) exists in two isoforms with distinct substrate preferences and tissue distributions. Which of the following correctly distinguishes MAO-A from MAO-B and explains the clinical selectivity of selegiline?

• A) MAO-A is expressed exclusively in the liver and intestinal wall, where it inactivates dietary monoamines (tyramine, tryptamine) before they enter the systemic circulation -- MAO-A inhibition by phenelzine at these sites produces the tyramine hypertensive crisis by allowing dietary tyramine to reach the systemic circulation; MAO-B is expressed exclusively in sympathetic nerve terminals, where it degrades NE after reuptake; selegiline selectively inhibits MAO-A at low doses, preserving intestinal tyramine inactivation and reducing the dietary tyramine restriction required with non-selective MAO inhibitors.
• B) MAO-A preferentially deaminates serotonin, norepinephrine, and dopamine and is the predominant isoform in sympathetic nerve terminals, intestinal wall, and liver; MAO-B preferentially deaminates dopamine, benzylamine, and phenylethylamine and is the predominant isoform in platelets, brain astrocytes, and serotonergic neurons; selegiline at low doses (up to 10 mg/day orally) selectively inhibits MAO-B, reducing dopamine catabolism in the striatum for Parkinson's disease without meaningfully inhibiting intestinal/hepatic MAO-A -- thus avoiding the dietary tyramine restriction required with non-selective MAO inhibitors (phenelzine, tranylcypromine); at high doses selegiline loses MAO-B selectivity and requires full dietary restriction.
• C) MAO-A and MAO-B have identical substrate preferences but differ in their cofactor requirements -- MAO-A requires FAD while MAO-B requires NAD+; the clinical distinction is that MAO-A inhibitors must be used with dietary tyramine restriction while MAO-B inhibitors do not, not because of different substrates but because FAD-dependent MAO-A is expressed in the intestinal wall while NAD+-dependent MAO-B is not.
• D) MAO-A preferentially deaminates dopamine and phenylethylamine and is expressed predominantly in the substantia nigra -- MAO-A inhibitors are therefore used in Parkinson's disease to reduce dopamine catabolism in the nigrostriatal pathway; MAO-B preferentially deaminates serotonin and NE and is expressed predominantly in sympathetic terminals and the intestinal wall -- MAO-B inhibitors require dietary tyramine restriction because MAO-B is the primary intestinal barrier to absorbed dietary tyramine.
• E) MAO-A and MAO-B are expressed on the outer mitochondrial membrane throughout the body but differ in their inhibitor sensitivity -- MAO-A is reversibly inhibited by moclobemide (an RIMA) while MAO-B is irreversibly inhibited by all currently available MAO inhibitors; selegiline is not actually MAO-B selective but rather produces fewer tyramine interactions than non-selective MAO inhibitors because its irreversible binding at MAO-A occurs more slowly than at MAO-B, giving intestinal MAO-A time to regenerate between dietary tyramine exposures.

5. Which of the following correctly defines the term false transmitter in the context of autonomic pharmacology, and identifies an agent that acts by this mechanism?

• A) A false transmitter is a drug that binds to the presynaptic autoreceptor (alpha-2) on sympathetic nerve terminals and mimics the inhibitory effect of endogenous NE on its own release -- clonidine is the prototype false transmitter, acting at presynaptic alpha-2 autoreceptors to reduce NE release without entering the biosynthetic pathway or being stored in vesicles.
• B) A false transmitter is a drug that blocks the postsynaptic adrenergic receptor with higher affinity than endogenous NE, thereby preventing NE from activating its target receptor -- prazosin is the prototype false transmitter at alpha-1 receptors and metoprolol is the prototype at beta-1 receptors; the term false transmitter reflects the fact that these antagonists occupy the receptor site without producing the biological response that NE would produce.
• C) A false transmitter is an exogenous substance that enters the catecholamine biosynthetic and storage pathway, is released by exocytosis alongside or instead of norepinephrine when the nerve fires, but produces a weaker or qualitatively different response than NE at the postsynaptic receptor -- methyldopa is converted to alpha-methylnorepinephrine (a false transmitter) in sympathetic neurons; alpha-methylnorepinephrine is stored in vesicles, released by nerve stimulation, and acts as a weaker alpha-1 agonist and a potent alpha-2 agonist, thereby reducing sympathetic outflow both peripherally and centrally.
• D) A false transmitter is an endogenous neuropeptide co-released with norepinephrine from sympathetic nerve terminals that modulates the postsynaptic response to NE -- neuropeptide Y (NPY) is the principal false transmitter at sympathetic terminals, acting at postsynaptic Y1 receptors to potentiate alpha-1-mediated vasoconstriction; the term false transmitter reflects the fact that NPY produces vasoconstriction through a receptor distinct from the adrenergic receptor activated by the primary transmitter NE.
• E) A false transmitter is a synthetic catecholamine analog that activates adrenergic receptors but cannot be degraded by either MAO or COMT, resulting in prolonged receptor activation -- isoproterenol is the prototype false transmitter at beta receptors; its resistance to catecholamine degradation enzymes accounts for the prolonged bronchodilation it produces compared to endogenous epinephrine.

6. Tyramine is an indirect sympathomimetic amine found in aged and fermented foods. Which of the following correctly describes the mechanism by which tyramine produces its sympathomimetic effect, and why this effect is dramatically amplified in patients taking non-selective MAO inhibitors?

• A) Tyramine crosses the blood-brain barrier and directly activates central alpha-1 adrenergic receptors in the RVLM vasomotor center, increasing sympathetic preganglionic outflow and producing systemic hypertension -- MAO inhibitors amplify this effect by preventing tyramine degradation in the brain, allowing it to accumulate and persistently activate central vasomotor neurons; dietary tyramine restriction is required because tyramine cannot be inactivated peripherally by any other mechanism once central MAO is inhibited.
• B) Tyramine is taken up into sympathetic nerve terminals via NET (Uptake 1), enters vesicles via VMAT2, and displaces stored norepinephrine from vesicles into the cytoplasm and then into the synapse through carrier-mediated release (not exocytosis) -- this NE displacement produces indirect sympathomimesis; under normal conditions, intestinal and hepatic MAO-A degrades dietary tyramine before it reaches sympathetic terminals, limiting its systemic effect; MAO inhibition abolishes this first-pass inactivation, allowing dietary tyramine to reach peripheral sympathetic terminals in concentrations sufficient to cause massive NE displacement and hypertensive crisis.
• C) Tyramine directly binds to and activates alpha-1 and beta-1 adrenergic receptors with lower affinity than norepinephrine, producing a mild direct sympathomimetic effect at normal dietary concentrations -- MAO inhibitors amplify this effect by blocking tyramine's primary metabolic inactivation pathway, causing tyramine blood levels to rise to concentrations sufficient to fully activate adrenergic receptors; the hypertensive crisis from MAOI-tyramine interaction reflects direct receptor activation at supraphysiological tyramine concentrations rather than any indirect NE-displacement mechanism.
• D) Tyramine inhibits NET on sympathetic nerve terminals, preventing NE reuptake and causing NE to accumulate in the synapse -- this indirect sympathomimesis by reuptake inhibition is identical to the mechanism of cocaine; MAO inhibitors amplify tyramine's effect by also blocking the vesicular storage of NE (since cytoplasmic MAO normally degrades any unpackaged NE), forcing all NE to remain in the synapse; the combination of reuptake inhibition plus impaired vesicular storage produces the hypertensive crisis.
• E) Tyramine activates presynaptic beta-2 adrenergic receptors on sympathetic nerve terminals, triggering cAMP-mediated enhancement of exocytotic NE release -- this presynaptic facilitatory mechanism produces indirect sympathomimesis; MAO inhibitors amplify the effect by preventing NE degradation after release, prolonging its action at postsynaptic receptors; the hypertensive crisis results from both enhanced release and impaired NE degradation acting simultaneously.

7. Acetylcholine synthesis and vesicular storage in cholinergic neurons differs fundamentally from catecholamine handling in adrenergic neurons. Which of the following correctly identifies the enzyme responsible for ACh synthesis, the transporter responsible for vesicular ACh storage, and the pharmacological agent that selectively blocks this vesicular transporter?

• A) Choline acetyltransferase (ChAT) synthesizes ACh from acetyl-CoA and choline in the cytoplasm of cholinergic neurons -- choline is the rate-limiting substrate and is transported into the neuron by the high-affinity choline transporter (CHT1) on the presynaptic membrane; ACh is then loaded into vesicles by the vesicular acetylcholine transporter (VAChT), which uses the proton gradient as its energy source; hemicholinium-3 blocks CHT1 (preventing choline uptake and thereby limiting ACh synthesis), while vesamicol blocks VAChT (preventing vesicular ACh loading without affecting synthesis).
• B) Choline acetyltransferase (ChAT) synthesizes ACh from acetyl-CoA and choline in the vesicle lumen rather than the cytoplasm -- newly synthesized ACh is immediately available for exocytotic release without requiring a separate vesicular loading step; vesamicol therefore has no effect on cholinergic transmission because vesicular packaging and synthesis occur simultaneously in the same compartment.
• C) Choline acetyltransferase (ChAT) synthesizes ACh from acetyl-CoA and choline; ACh is stored in vesicles by VMAT2, the same vesicular transporter used for catecholamine storage in adrenergic neurons -- this shared vesicular transporter explains why reserpine, which inhibits VMAT2, depletes both NE stores in adrenergic neurons and ACh stores in cholinergic neurons, producing a combined adrenergic and cholinergic deficit.
• D) Choline acetyltransferase (ChAT) synthesizes acetylcholine from acetyl-CoA and choline in the cytoplasm -- this is the rate-limiting step in ACh production and ChAT activity is reduced in Alzheimer's disease, contributing to cholinergic deficits; the vesicular acetylcholine transporter (VAChT) loads ACh into synaptic vesicles using the proton electrochemical gradient; vesamicol blocks VAChT, preventing vesicular ACh loading and depleting releasable ACh stores; hemicholinium-3 blocks the high-affinity choline transporter CHT1, reducing choline availability for ACh synthesis and causing presynaptic depletion during high-frequency stimulation.
• E) Acetyl-CoA carboxylase synthesizes the acetyl group donor required for ACh production in all cholinergic neurons -- inhibition of acetyl-CoA carboxylase by statins explains the myopathy and autonomic dysfunction that occasionally complicates statin therapy, as reduced acetyl-CoA availability impairs ACh synthesis at both neuromuscular junctions and autonomic ganglia.

8. Which of the following correctly identifies the two enzymatic pathways responsible for catecholamine degradation and the primary metabolite produced from norepinephrine metabolism in each pathway?

• A) Catecholamines are degraded by two sequential enzymes that must act in order: MAO must always act before COMT, because MAO produces the aldehyde intermediate that COMT then methylates; this obligatory sequential pathway means that MAO inhibitors completely prevent all catecholamine degradation, since COMT cannot act without the MAO-produced intermediate; the final metabolite of NE degradation is homovanillic acid (HVA), which is measured in urine to assess sympathetic activity.
• B) Monoamine oxidase (MAO, on the outer mitochondrial membrane) and catechol-O-methyltransferase (COMT, cytoplasmic and extracellular) both degrade catecholamines but can act independently and in either order -- MAO oxidatively deaminates the ethylamine side chain producing an aldehyde intermediate that is further reduced to MHPG or oxidized to VMA; COMT methylates the 3-hydroxyl group of the catechol ring producing normetanephrine (from NE) or metanephrine (from epinephrine); the principal urinary metabolite of NE from neuronal degradation is vanillylmandelic acid (VMA), while normetanephrine and metanephrine (metanephrines) measured in plasma or urine are the most sensitive markers for pheochromocytoma.
• C) MAO is the only enzyme capable of degrading norepinephrine -- COMT methylates only dopamine and epinephrine but cannot act on NE because NE lacks the N-methyl group required for COMT recognition; MAO inhibition therefore completely prevents NE degradation, which is why MAOI antidepressants produce prolonged NE action and require dietary tyramine restriction to prevent hypertensive crisis from uncontrolled NE accumulation.
• D) COMT is the primary degradative enzyme for circulating catecholamines (producing normetanephrine from NE and metanephrine from epinephrine), while MAO is the primary degradative enzyme for intraneuronal catecholamines after reuptake into sympathetic terminals; the clinical measurement of plasma metanephrines (reflecting COMT activity on chromaffin cell-secreted catecholamines) has higher sensitivity for pheochromocytoma than urinary catecholamines because pheochromocytoma cells constitutively express COMT and continuously produce metanephrines even during periods of non-secretion.
• E) Catecholamines are degraded exclusively by MAO within sympathetic nerve terminals after reuptake via NET -- COMT is not a genuine degradative enzyme but rather a regulatory methyltransferase that modulates catecholamine receptor sensitivity by methylating the catechol ring of receptor-bound catecholamines while they are still occupying the receptor; COMT inhibitors (entacapone, tolcapone) therefore prolong catecholamine receptor activation rather than preventing peripheral catecholamine degradation.